BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34325344)

  • 1. Virus discovery in chronic inflammatory demyelinating polyneuropathy.
    van Lieverloo GGA; Wieske L; van Schaik IN; Deijs M; van der Hoek L; Eftimov F
    J Neuroimmunol; 2021 Sep; 358():577668. PubMed ID: 34325344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients.
    Alessandro L; Pastor Rueda JM; Wilken M; Querol L; Marrodán M; Acosta JN; Rivero A; Barroso F; Farez MF
    J Peripher Nerv Syst; 2018 Sep; 23(3):154-158. PubMed ID: 29603827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay.
    Kmezic I; Gustafsson R; Fink K; Svenningsson A; Samuelsson K; Ingre C; Olsson T; Hansson M; Kockum I; Adzemovic MZ; Press R
    Front Immunol; 2023; 14():1241199. PubMed ID: 38077366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
    Zhang HL; Zhang XM; Mao XJ; Deng H; Li HF; Press R; Fredrikson S; Zhu J
    Acta Neurol Scand; 2012 Feb; 125(2):129-35. PubMed ID: 21434877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy.
    Sainaghi PP; Collimedaglia L; Alciato F; Leone MA; Naldi P; Molinari R; Monaco F; Avanzi GC
    Cytokine; 2010 Aug; 51(2):138-43. PubMed ID: 20538476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK cells in pathogenesis.
    Blum S; Csurhes P; McCombe P
    J Neuroimmunol; 2015 Aug; 285():53-6. PubMed ID: 26198918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome.
    Odaka M; Yuki N; Hirata K
    J Neurol; 2003 Aug; 250(8):913-6. PubMed ID: 12928908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 8, a Biomarker to Differentiate Guillain-Barré Syndrome From CIDP.
    Breville G; Lascano AM; Roux-Lombard P; Vuilleumier N; Lalive PH
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34140310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.
    Ruts L; Drenthen J; Jacobs BC; van Doorn PA;
    Neurology; 2010 May; 74(21):1680-6. PubMed ID: 20427754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.
    Kmezic I; Samuelsson K; Finn A; Upate Z; Blennow K; Zetterberg H; Press R
    Eur J Neurol; 2022 Sep; 29(9):2810-2822. PubMed ID: 35638376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS.
    Capodivento G; De Michelis C; Carpo M; Fancellu R; Schirinzi E; Severi D; Visigalli D; Franciotta D; Manganelli F; Siciliano G; Beronio A; Capello E; Lanteri P; Nobile-Orazio E; Schenone A; Benedetti L; Nobbio L
    J Neurol Neurosurg Psychiatry; 2021 Mar; 92(3):303-310. PubMed ID: 33093191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective Fas-mediated T-cell apoptosis predicts acute onset CIDP.
    Comi C; Osio M; Ferretti M; Mesturini R; Cappellano G; Chiocchetti A; Carecchio M; Nascimbene C; Varrasi C; Cantello R; Mariani C; Monaco F; Dianzani U
    J Peripher Nerv Syst; 2009 Jun; 14(2):101-6. PubMed ID: 19691532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuropathy].
    Kanbayashi T; Sonoo M
    Brain Nerve; 2015 Nov; 67(11):1388-96. PubMed ID: 26560954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Press R; Pashenkov M; Jin JP; Link H
    J Clin Immunol; 2003 Jul; 23(4):259-67. PubMed ID: 12959218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study on the role of serum uric acid in differentiating acute inflammatory demyelinating polyneuropathy from acute-onset chronic inflammatory demyelinating polyneuropathy.
    Zhang W; Tao W; Wang J; Nie P; Duan L; Yan L
    Eur J Neurol; 2024 May; 31(5):e16222. PubMed ID: 38356316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-8 as a potential biomarker in Guillain-Barre Syndrome.
    Breville G; Lascano AM; Roux-Lombard P; Lalive PH
    Eur Cytokine Netw; 2019 Dec; 30(4):130-134. PubMed ID: 32096474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Csurhes PA; Sullivan AA; Green K; Pender MP; McCombe PA
    J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1431-9. PubMed ID: 16170091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute-onset chronic inflammatory demyelinating polyneuropathy: An electrodiagnostic study.
    Anadani M; Katirji B
    Muscle Nerve; 2015 Nov; 52(5):900-5. PubMed ID: 25809534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation Between Guillain-Barré Syndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis-a Prospective Follow-up Study Using Ultrasound and Neurophysiological Measurements.
    Grimm A; Oertl H; Auffenberg E; Schubert V; Ruschil C; Axer H; Winter N
    Neurotherapeutics; 2019 Jul; 16(3):838-847. PubMed ID: 30756363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression Analysis of Protein Inhibitor of Activated STAT in Inflammatory Demyelinating Polyradiculoneuropathy.
    Ghafouri-Fard S; Hussen BM; Nicknafs F; Nazer N; Sayad A; Taheri M
    Front Immunol; 2021; 12():659038. PubMed ID: 34054823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.